Dear Colleagues,
Cancer is still one of the most critical issues for public health. Unlike the other diseases, the cancer cells are heterogeneous that bring unpredictable varieties, causing great difficulties for diagnosis and therapy via targeted approaches. Tumor microenvironment (TME) generally consists of tumor extracellular matrix, immune cells and tumor blood vessels, etc., which closely interact with cancer cells. The detection of the malignant area could be achieved by targeting TME. However, available probes fail to identify cancerous tissues without specificity. Notably, the emergence of advanced nanomaterials has dramatically promoted tumor targeting efficiency. With ingenious design and functionalizations, the novel nanomedicine would be a feasible strategy for cancer imaging and image-guided interventions. Therefore, the development of TME-responsive and TME-targeted nanomedicine could provide new avenues for cancer diagnosis and theranostics.
Therefore, we aim to highlight the most recent TME-responsive and TME-targeted nanomedicine applied for cancer imaging, in combination with theragnostic nanoagents for shaping TME. We welcome original research articles, Review articles and Mini Reviews. Topics include but are not limited to the following:
• Stimuli-responsive nanomedicine (acidic, redox, hypoxic, esterase, etc.) for cancer imaging
• Nanomedicine for monitoring Tumor-infiltrating immune cells (tumor-associated macrophage, T cells, DCs, etc.)
• Tumor vessel targeted (Integrin, nucleolin, VEGF-2 receptors, etc.) imaging via nanomedicine
• Immune cell-based nanomedicine (immune cell attaching, loading, immune cell membrane coating nanomedicine) for cancer imaging
• Smart nanomedicine for TME theranostics (shaping TME, remodeling immune cells and normalizing tumor vessels, etc.)
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Dear Colleagues,
Cancer is still one of the most critical issues for public health. Unlike the other diseases, the cancer cells are heterogeneous that bring unpredictable varieties, causing great difficulties for diagnosis and therapy via targeted approaches. Tumor microenvironment (TME) generally consists of tumor extracellular matrix, immune cells and tumor blood vessels, etc., which closely interact with cancer cells. The detection of the malignant area could be achieved by targeting TME. However, available probes fail to identify cancerous tissues without specificity. Notably, the emergence of advanced nanomaterials has dramatically promoted tumor targeting efficiency. With ingenious design and functionalizations, the novel nanomedicine would be a feasible strategy for cancer imaging and image-guided interventions. Therefore, the development of TME-responsive and TME-targeted nanomedicine could provide new avenues for cancer diagnosis and theranostics.
Therefore, we aim to highlight the most recent TME-responsive and TME-targeted nanomedicine applied for cancer imaging, in combination with theragnostic nanoagents for shaping TME. We welcome original research articles, Review articles and Mini Reviews. Topics include but are not limited to the following:
• Stimuli-responsive nanomedicine (acidic, redox, hypoxic, esterase, etc.) for cancer imaging
• Nanomedicine for monitoring Tumor-infiltrating immune cells (tumor-associated macrophage, T cells, DCs, etc.)
• Tumor vessel targeted (Integrin, nucleolin, VEGF-2 receptors, etc.) imaging via nanomedicine
• Immune cell-based nanomedicine (immune cell attaching, loading, immune cell membrane coating nanomedicine) for cancer imaging
• Smart nanomedicine for TME theranostics (shaping TME, remodeling immune cells and normalizing tumor vessels, etc.)
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.